• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Working here

























Listen skipper we gained today what we lost over the last 3 weeks. There is no need to be bullish on supernus right now.

Overall, it continues to do worse. At one point, it was up to 57 dollars a share years ago at its high and its never even been above 25 dollars now for as long as I can remember. I don’t think supernus stock is ever going to really climb, but continue to fall especially in these times.
 




Overall, it continues to do worse. At one point, it was up to 57 dollars a share years ago at its high and its never even been above 25 dollars now for as long as I can remember. I don’t think supernus stock is ever going to really climb, but continue to fall especially in these times.

“Stock was high. Now it low. Can never be high again.”